3
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasms
10
Lung Neoplasms
9
Colorectal Neoplasms
7
Breast Neoplasms
7
Prostatic Neoplasms
6
Rectal Neoplasms
3
Polycystic Ovary Syndrome
3
Neoplasm Metastasis
3
Colonic Neoplasms
3
Stomach Neoplasms
2
Smoking Cessation
2
Neoplastic Cells, Circulating
2
Motor Activity
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia
2
Endometrial Neoplasms
2
Disease
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Venous Thromboembolism
1
Vaginal Neoplasms
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
1
Testicular Germ Cell Tumor
1
Stroke
1
Solitary Pulmonary Nodule
1
Skin Neoplasms
1
Sezary Syndrome
1
Interventions
pembrolizumab
12
Radiotherapy
9
avelumab
8
Nivolumab
8
cemiplimab
4
Radiation
4
Ipilimumab
4
poly ICLC
3
atezolizumab
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Cyclophosphamide
3
talimogene laherparepvec
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
aldesleukin
2
Interferon-beta
2
Immunoglobulin G
2
Immune Checkpoint Inhibitors
2
Cisplatin
2
Carboplatin
2
Biopsy
2
veliparib
1
vatalanib
1
tremelimumab
1
tocilizumab
1
temsirolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Merkel Cell
×
Hematologic Tests
×
Clear all
NCT06448611
2024-06-13
MERCCALIBI
University Hospital, Montpellier
Not yet recruiting
25 enrolled